secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inari Medical, Inc. (—)
CIK:        0001531048
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001531048-24-000050
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inari Medical CFO Mitch Hill to retire Oct 1, succeeded by Kevin Strange
------------------------------------------------------------------------

- Hill retires as CFO effective Oct 1, 2024; will stay in non-executive role through Jan 2, 2025 to assist transition.
- Kevin Strange, current SVP Finance, Accounting, Strategy and BD, appointed new CFO effective Oct 1, 2024.
- Strange compensation: $480k base salary, target bonus 60% of base, $250k RSU grant vesting over 4 years, $300k relocation bonus.
- Strange has over 15 years med device finance experience; previously at Boston Scientific, Wells Fargo, and Medtronic.
- Transition is orderly; Hill led IPO in May 2020 and developed Strange as successor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1531048/000153104824000050/0001531048-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1531048/000153104824000050/nari-20240724.htm
  HTML page:      https://secwatch.observer/filing/0001531048-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer